Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
G3T-001
- Development stage
- Preclinical
- Lead developer
- Global Genomics
01
Overview
G3T-001 is a preclinical drug candidate developed by G3 Therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and cardiovascular diseases, including coronary artery disease (CAD). The drug targets a novel, genetically validated biological mechanism that addresses both liver and cardiovascular pathology, offering a distinct approach from traditional cholesterol-lowering therapies. Identified through G3 Therapeutics' discovery platform, G3T-001 is currently undergoing preclinical validation to explore its potential in treating metabolic and heart diseases simultaneously.
- Other names
- unnamed novel candidate
Beyond the preview
Go deeper on G3T-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on G3T-001.